1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug Eluting Balloon Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug Eluting Balloon Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Drug Eluting Balloon Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2023-2031
6.3.1. Coronary Drug Eluting Balloon
6.3.2. Peripheral Drug Eluting Balloon
6.3.3. Others
6.4. Market Attractiveness, by Product
7. Drug Eluting Balloon Market Analysis and Forecast, by Technology
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2023-2031
7.3.1. Paccocath
7.3.2. FreePac
7.3.3. TransPax
7.3.4. EnduraCoat
7.3.5. Others
7.4. Market Attractiveness, by Technology
8. Global Drug Eluting Balloon Market Analysis and Forecast, by End-user
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2023-2031
8.3.1. Hospitals and Ambulatory Surgery Centers
8.3.2. Cath Labs
8.3.3. Others
8.4. Market Attractiveness, by End-user
9. Global Drug Eluting Balloon Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Drug Eluting Balloon Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2023-2031
10.2.1. Coronary Drug Eluting Balloon
10.2.2. Peripheral Drug Eluting Balloon
10.2.3. Others
10.3. Market Attractiveness, by Product
10.4. Market Value Forecast, by Technology, 2023-2031
10.4.1. Paccocath
10.4.2. FreePac
10.4.3. TransPax
10.4.4. EnduraCoat
10.4.5. Others
10.5. Market Attractiveness, by Technology
10.6. Market Value Forecast, by End-user, 2023-2031
10.6.1. Hospitals and Ambulatory Surgery Centers
10.6.2. Cath Labs
10.6.3. Others
10.7. Market Attractiveness, by End-user
10.8. Market Value Forecast, by Country, 2023-2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Product
10.9.2. By Technology
10.9.3. By End-user
10.9.4. By Country
11. Europe Drug Eluting Balloon Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2023-2031
11.2.1. Coronary Drug Eluting Balloon
11.2.2. Peripheral Drug Eluting Balloon
11.2.3. Others
11.3. Market Attractiveness, by Product
11.4. Market Value Forecast, by Technology, 2023-2031
11.4.1. Paccocath
11.4.2. FreePac
11.4.3. TransPax
11.4.4. EnduraCoat
11.4.5. Others
11.5. Market Attractiveness, by Technology
11.6. Market Value Forecast, by End-user, 2023-2031
11.6.1. Hospitals and Ambulatory Surgery Centers
11.6.2. Cath Labs
11.6.3. Others
11.7. Market Attractiveness, by End-user
11.8. Market Value Forecast, by Country/Sub-region, 2023-2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Product
11.9.2. By Technology
11.9.3. By End-user
11.9.4. By Country/Sub-region
12. Asia Pacific Drug Eluting Balloon Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2023-2031
12.2.1. Coronary Drug Eluting Balloon
12.2.2. Peripheral Drug Eluting Balloon
12.2.3. Others
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Technology, 2023-2031
12.4.1. Paccocath
12.4.2. FreePac
12.4.3. TransPax
12.4.4. EnduraCoat
12.4.5. Others
12.5. Market Attractiveness, by Technology
12.6. Market Value Forecast, by End-user, 2023-2031
12.6.1. Hospitals and Ambulatory Surgery Centers
12.6.2. Cath Labs
12.6.3. Others
12.7. Market Attractiveness, by End-user
12.8. Market Value Forecast, by Country/Sub-region, 2023-2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Product
12.9.2. By Technology
12.9.3. By End-user
12.9.4. By Country/Sub-region
13. Latin America Drug Eluting Balloon Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2023-2031
13.2.1. Coronary Drug Eluting Balloon
13.2.2. Peripheral Drug Eluting Balloon
13.2.3. Others
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Technology, 2023-2031
13.4.1. Paccocath
13.4.2. FreePac
13.4.3. TransPax
13.4.4. EnduraCoat
13.4.5. Others
13.5. Market Attractiveness, by Technology
13.6. Market Value Forecast, by End-user, 2023-2031
13.6.1. Hospitals and Ambulatory Surgery Centers
13.6.2. Cath Labs
13.6.3. Others
13.7. Market Attractiveness, by End-user
13.8. Market Value Forecast, by Country/Sub-region, 2023-2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Product
13.9.2. By Technology
13.9.3. By End-user
13.9.4. By Country/Sub-region
14. Middle East & Africa Drug Eluting Balloon Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2023-2031
14.2.1. Coronary Drug Eluting Balloon
14.2.2. Peripheral Drug Eluting Balloon
14.2.3. Others
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Technology, 2023-2031
14.4.1. Paccocath
14.4.2. FreePac
14.4.3. TransPax
14.4.4. EnduraCoat
14.4.5. Others
14.5. Market Attractiveness, by Technology
14.6. Market Value Forecast, by End-user, 2023-2031
14.6.1. Hospitals and Ambulatory Surgery Centers
14.6.2. Cath Labs
14.6.3. Others
14.7. Market Attractiveness, by End-user
14.8. Market Value Forecast, by Country/Sub-region, 2023-2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Product
14.9.2. By Technology
14.9.3. By End-user
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Medtronic
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. B. Braun Melsungen AG
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Cook Medical, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Boston Scientific Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Becton, Dickson and Company
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. EuroCor
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Terumo Corporation
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Koninklijke Philips N.V.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer